EPISODE SUMMARY For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon? Guests: Jeffrey Galvin, American Gene Technologies Anthony Fauci, National Institute of Allergy and Infectious Diseases EPISODE NOTES For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?
American Gene Technologies’ goal to develop a cure for HIV moved one step closer to reality. After infusing the first patient with its cell therapy candidate AGT103-T, the company announced the Data and Safety Monitoring Board unanimously supported the continuation of the clinical study without modification.
American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
One year after receiving the green light from the FDA to initiate a Phase I study of an HIV gene therapy, American Gene Technologies (AGT) has infused the first patient. AGT103-T is designed as a cure for the disease that has wreaked havoc across the globe since the 1980s.
American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease. This investment places Gaingels alongside private investors who believe deeply in AGT’s mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.
Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.
The state of Maryland is the global epicenter of vaccine research and development. This has never been more evident than right now as scores of Maryland companies have risen to the global challenge of developing the first approved vaccine for SARS-CoV-2.
Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups.